Literature DB >> 33309547

Addressing the contralateral neck for ipsilateral disease recurrence in oral cavity cancers.

Hitesh Rajendra Singhavi1, Sudhir Nair2, Manish Mair3, Rachit Mathur4, Arjun Singh4, Ameya Pai4, Akshay Patil5, Deepa Nair4, Pankaj Chaturvedi4.   

Abstract

BACKGROUND: Evidence for performing contralateral neck dissection (CND) of recurrent oral cavity squamous cell cancers (OCSCC) is lacking.
MATERIAL AND METHODS: This is a retrospective study of 78 consecutive OCSCC having ipsilateral recurrence recorded over five years. We screened 1658 OCSCC patients and selected those patients who underwent CND as part of treatment for ipsilateral recurrence.
RESULTS: The median disease-free interval was 32 months. Incidence of contralateral nodal metastasis (CNM) in recurrent OCSCC was 23.1% and of which 14% were occult. The factor significantly influencing CNM was the depth of invasion (DOI) > 10 mm (p < 0.01). In our study, imaging had suboptimal PPV (33%) while it had high NPV (88%) in diagnosing nodal metastasis in recurrent OCSCC.
CONCLUSION: DOI is the most important factor predicting CNM in case of ipsilateral primary recurrence. PET-CECT has a high NPV and contralateral neck should be addressed in case of tumours with higher DOI.
Copyright © 2020 Elsevier Ltd, BASO ~ The Association for Cancer Surgery, and the European Society of Surgical Oncology. All rights reserved.

Entities:  

Keywords:  Contralateral nodal metastasis; Depth of invasion; Oral cancer; Recurrences; Survival

Year:  2020        PMID: 33309547     DOI: 10.1016/j.ejso.2020.11.143

Source DB:  PubMed          Journal:  Eur J Surg Oncol        ISSN: 0748-7983            Impact factor:   4.424


  1 in total

1.  Treatment and Prognosis of Oral Cancer Patients with Confirmed Contralateral Neck Metastasis: A Multicenter Retrospective Analysis.

Authors:  Yuki Sakamoto; Mitsunobu Otsuru; Takumi Hasegawa; Masaya Akashi; Shin-Ichi Yamada; Hiroshi Kurita; Masaya Okura; Nobuhiro Yamakawa; Tadaaki Kirita; Souichi Yanamoto; Masahiro Umeda; Yuka Kojima
Journal:  Int J Environ Res Public Health       Date:  2022-07-28       Impact factor: 4.614

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.